The progression of benign prostatic hyperplasia: examining the evidence and determining the risk

DOI: 10.1159/000052475
European Urology, 2001, 39, 390-9.

#	Paper	IF	Citations
114	Recent developments in guidelines on benign prostatic hyperplasia. **2002**, 12, 3-6		9
113	Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. **2002**, 60, 434-41		578
112	Introduction and Conclusions. **2002**, 1, 1-4		
111	Potential Role of 1-Adrenoceptors in the Aetiology of LUTS. **2002**, 1, 5-13		19
110	Obstructive Bladder Dysfunction: Morphological, Biochemical and Molecular Changes. **2002**, 1, 14-20		37
109	Managing the Consequences of Obstruction. **2002**, 1, 21-27		15
108	LUTS, the Case Is Altered. **2002**, 1, 28-35		6
107	Benign Prostatic Hyperplasia. **2002**, 20, 268-272		1
106	The urologist view of BPH progression: results of an international survey. *European Urology*, **2002**, 41, 490-6	10.2	26
105	Ultrasonic measurement of bladder weight as a possible predictor of acute urinary retention in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. **2002**, 28, 985-90		28
104	Drug treatment of benign prostatic hyperplasia and hospital admission for BPH-related surgery. *European Urology*, **2003**, 43, 528-34	10.2	40
103	Benign prostatic hyperplasia: a progressive disease of aging men. **2003**, 61, 267-73		155
102	Natural history of lower urinary tract symptoms in men--result of a longitudinal community-based study in Japan. **2003**, 61, 956-60		25
101	Lower urinary tract symptoms/benign prostatic hyperplasia: maintaining symptom control and reducing complications. **2003**, 62, 15-23		53
100	Identifying Patients with Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia (LUTS/BPH) at Risk for Progression. **2003**, 2, 6-12		13
99	Protecting Bladder Function and Reducing Disease Progression. **2003**, 2, 13-18		4
98	The potential of serum prostate-specific antigen as a predictor of clinical response in patients with lower urinary tract symptoms and benign prostatic hyperplasia. **2004**, 93 Suppl 1, 21-6		12

97	Consensus statement: the role of prostate-specific antigen in managing the patient with benign prostatic hyperplasia. **2004**, 93 Suppl 1, 27-9		34
96	Optimising the medical management of benign prostatic hyperplasia. *European Urology*, **2004**, 45, 411-9	10.2	37
95	EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). *European Urology*, **2004**, 46, 547-54	10.2	435
94	Predictive medicine in non-malignant urological disorders. **2004**, 21, 369-76		1
93	[Urological illnesses in the elderly]. **2004**, 43, 916-21		
92	Benign prostatic hyperplasia. **2004**, 124, 222-7		8
91	Benign prostatic hyperplasia progression and its impact on treatment. **2004**, 14, 45-50		14
90	Could self-management challenge pharmacotherapy as a long-term treatment for uncomplicated lower urinary tract symptoms?. **2004**, 14, 7-12		7
89	Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in relation to the patient's risk profile for progression. **2005**, 95 Suppl 4, 6-11		18
88	Fact or fiction: What do the benign prostatic hyperplasia data tell us?. **2005**, 3, 71-78		
87	Fact or fiction: what do the benign prostatic hyperplasia data tell us?. **2005**, 6, 243-50		
86	Limitations of using outcomes in the placebo arm of a clinical trial of benign prostatic hyperplasia to quantify those in the community. **2005**, 80, 759-64		15
85	Limitations of Using Outcomes in the Placebo Arm of a Clinical Trial of Benign Prostatic Hyperplasia to Quantify Those in the Community. **2005**, 80, 759-764		11
84	Dutasteride improves objective and subjective disease measures in men with benign prostatic hyperplasia and modest or severe prostate enlargement. **2006**, 176, 1045-50; discussion 1050		20
83	[Validity of tests for initial diagnosis and its concordance with final diagnosis in patients with suspected benign prostatic hyperplasia]. **2006**, 30, 667-74		9
82	Risk Assessment and Medical Management of Acute Urinary Retention in Patients with Benign Prostatic Hyperplasia. **2006**, 4, 109-116		1
81	Delayed surgical treatment of benign prostatic hyperplasia: a subjective estimation of change in the operative risk profile. **2006**, 3, 271-278		1
80	Benign Prostatic Hypertrophy: A Progressive Pathology. Hypothesis for a Preventive Therapy. **2006**, 73, 257-264		1

79	Comparison of intravesical prostatic protrusion, prostate volume and serum prostatic-specific antigen in the evaluation of bladder outlet obstruction. **2006**, 13, 1509-13		82
78	Managing enlarged prostate in primary care. **2006**, 60, 1609-15		6
77	BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial. *European Urology*, **2006**, 49, 82-6	10.2	70
76	Acute urinary retention: developing an A&E management pathway. **2006**, 15, 434-8		5
75	Drug Insight: 5alpha-reductase inhibitors for the treatment of benign prostatic hyperplasia. **2006**, 3, 495-503		42
74	Medical and minimally invasive therapies for the treatment of benign prostatic hyperplasia. **2006**, 9, 204-14		18
73	5alpha-reductase inhibition for men with enlarged prostate. **2007**, 19, 398-407		2
72	The long-term outcome of medical therapy for BPH. *European Urology*, **2007**, 51, 1522-33	10.2	80
71	Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management. **2008**, 62, 1076-86		102
70	Finasteride in the treatment of patients with benign prostatic hyperplasia: a review. **2009**, 5, 535-45		19
69	[Diagnostic and differential diagnosis of benign prostate syndrome (BPS): guidelines of the German Urologists]. **2009**, 48, 1356-60, 1362-4		18
68	A broader role for 5ARIs in prostate disease? Existing evidence and emerging benefits. **2009**, 69, 895-907		12
67	Can simple tests performed in the primary care setting provide accurate and efficient diagnosis of benign prostatic hyperplasia? Rationale and design of the Diagnosis Improvement in Primary Care Trial. **2009**, 63, 1192-7		7
66	Changes in prostate volume in Japanese patients with benign prostatic hyperplasia: association with other urological measures and risk of surgical intervention. **2009**, 16, 622-7		6
65	Evaluating use patterns of and adherence to medications for benign prostatic hyperplasia. **2009**, 181, 2214-21; discussion 2221-2		49
64	Extracts of various species of Epilobium inhibit proliferation of human prostate cells. **2003**, 55, 683-90		43
63	Antioxidant levels of common fruits, vegetables, and juices versus protective activity against in vitro ischemia/reperfusion. **2010**, 42, 409-15		19
62	Managing benign prostatic hyperplasia and prostate cancer the challenges today. **2010**, 7, 113-124		1

61	Effect of a hypercholesterolemic diet on serum lipid profile, plasma sex steroid levels, and prostate structure in rats. **2010**, 76, 1517.e1-5	14
60	Progression of null or mild lower urinary tract symptoms indicative of benign prostatic hyperplasia after 2 years of follow-up in non-treated men aged 40 years or older. **2011**, 77, 693-8	4
59	Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial. **2011**, 78, 641-6	21
58	Retenciones agudas de orina completas. **2011**, 43, 1-13	
57	Review of dutasteride/tamsulosin fixed-dose combination for the treatment of benign prostatic hyperplasia: efficacy, safety, and patient acceptability. **2011**, 5, 483-90	13
56	Efficacy and Tolerability of Tamsulosin 0.4 mg in Patients with Symptomatic Benign Prostatic Hyperplasia. **2011**, 52, 479-84	9
55	Rétentions aiguës d'urine complètes. **2011**, 4, 1-12	1
54	Associations between variants in the cyclooxygenase 2 enzyme gene (PTGS2) and development of benign prostate enlargement. **2011**, 108, 1610-5	5
53	Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). **2011**, 108, 388-94	139
52	Age-related changes in prostate zonal volumes as measured by high-resolution magnetic resonance imaging (MRI): a cross-sectional study in over 500 patients. **2012**, 110, 1642-7	39
51	[Diagnostics of benign prostate syndrome]. **2013**, 52, 193-6	
50	Involvement of fibroblast growth factor receptor genes in benign prostate hyperplasia in a Korean population. **2013**, 35, 869-75	3
49	[Clinical outcomes after combined therapy with dutasteride in patients with unsuccessful trial without catheter after treatment with an alpha1-adrenergic receptor blocker monotherapy for acute urinary retention caused by prostatic hyperplasia]. *Japanese Journal of Urology*, **2014**, 105, 190-5	1
48	Progressive Improvement of T-Scores in Men with Osteoporosis and Subnormal Serum Testosterone Levels upon Treatment with Testosterone over Six Years. **2014**, 2014, 496948	24
47	Evaluation of the clinical indications, adverse drug reactions, and finasteride use in patients with benign prostatic hyperplasia in Poland. **2014**, 66, 565-9	4
46	Effectiveness of tadalafil 5 mg once daily in the treatment of men with lower urinary tract symptoms suggestive to benign prostatic hyperplasia with or without erectile dysfunction: results from naturalistic observational TadaLutsEd study. **2014**, 11, 498-505	12
45	Actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia: temporal trends of prescription and hospitalization rates over 5 years in a large population of Italian men. **2014**, 46, 695-701	22
44	Ritenzione acuta di urina. **2014**, 18, 1-11	

43	What do we know about phytotherapy of benign prostatic hyperplasia?. **2015**, 126, 42-56		49
42	Baseline characteristics predict risk of progression and response to combined medical therapy for benign prostatic hyperplasia (BPH). **2015**, 115, 308-16		32
41	Extract Induces Cell Apoptosis and Inhibits COX-2 Expression in a Rat Model of Benign Prostatic Hyperplasia. **2016**, 8, e39284		6
40	Does Prostate Size Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from the REDUCE Trial. *European Urology*, **2016**, 69, 885-91	10.2	18
39	The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract Symptoms: Prevalence and Incident Rates. **2016**, 43, 289-97		232
38	Diagnostic Work-Up of Lower Urinary Tract Symptoms. **2016**, 43, 299-309		4
37	Change of Ultrasound Estimated Bladder Weight and Bladder Wall Thickness After Treatment of Bladder Outlet Obstruction With Dutasteride. **2017**, 9, 67-74		1
36	Does Peak Urine Flow Rate Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from REDUCE. **2017**, 198, 650-656		0
35	Sintomatología urinaria en pacientes con hiperplasia prostática posterior a una intervención educativa. **2017**, 24, 112-115		
34	Prostate Zonal Volumetry as a Predictor of Clinical Outcomes for Prostate Artery Embolization. **2017**, 40, 245-251		30
33	The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia. **2018**, 5, 28-32		38
32	Canadian Urological Association guideline on male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH): 2018 update. *Canadian Urological Association Journal*, **2018**, 12, 303-312	1.2	40
31	PSA predicts development of incident lower urinary tract symptoms: results from the REDUCE study. **2018**, 21, 238-244		7
30	Androgens and Benign Prostatic Hyperplasia. **2018**, 775-783		
29	M2 macrophage-mediated interleukin-4 signalling induces myofibroblast phenotype during the progression of benign prostatic hyperplasia. **2018**, 9, 755		9
28	Meta-Analysis of Efficacy and Safety of Tadalafil Plus Tamsulosin Compared with Tadalafil Alone in Treating Men with Benign Prostatic Hyperplasia and Erectile Dysfunction. **2019**, 13, 1557988319882597		8
27	Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia. **2019**, 19, 17		8
26	Relationship between Lower Urinary Tract Symptoms and Prostatic Urethral Stiffness Using Strain Elastography: Initial Experiences. **2019**, 8,		2

25	The inflammation patterns of different inflammatory cells in histological structures of hyperplasic prostatic tissues. **2020**, 9, 1639-1649		5
24	The possible association between serum interleukin 8 and acute urinary retention in Chinese patients with benign prostatic hyperplasia. **2020**, 52, e13763		2
23	Efficacy and Safety of Combination Comprising Tamsulosin and PDE5-Is, Relative to Monotherapies, in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction Associated With Benign Prostatic Hyperplasia: A Meta-Analysis. **2020**, 14, 1557988320980180		2
22	Serum interleukin 6 and acute urinary retention in elderly men with benign prostatic hyperplasia in China: a cross-sectional study. **2021**, 10, 455-465		3
21	Correlation of prostatic morphological parameters and clinical progression in aging Chinese men with benign prostatic hyperplasia: Results from a cross-sectional study. **2021**, 81, 478-486		0
20	Epilobium angustifolium L. extract with high content in oenothein B on benign prostatic hyperplasia: A monocentric, randomized, double-blind, placebo-controlled clinical trial. **2021**, 138, 111414		8
19	Prolieve Transurethral Thermodilatation for treatment of Symptomatic Benign Prostatic Hyperplasia: 5-Year Results from a Prospective Multicenter Trial. **2021**,		1
18	SIGNIFICANCE OF NON-INVASIVE SONO-MORPHOLOGICAL MARKERS IN THE EVALUATION OF BLADDER OUTLET OBSTRUCTION AND ACUTE URINARY RETENTION SECONDARY TO BENIGN PROSTATIC HYPERPLASIA. **2021**, 5-9		
17	Role of Acoustic Radiation Force Impulse (ARFI) Elastography in Determination of Severity of Benign Prostate Hyperplasia. **2016**, 22, 4523-4528		7
16	Efficacy and safety of dutasteride compared with finasteride in treating males with benign prostatic hyperplasia: A meta-analysis of randomized controlled trials. **2020**, 20, 1566-1574		4
15	Analysis of initial baseline clinical parameters and treatment strategy associated with medication failure in the treatment of benign prostatic hyperplasia in Korea. **2010**, 14, 261-6		5
14	The Correlation Between Prostate Volume in Patients with Benign Prostatic Hyperplasia in Relation to Erectile Dysfunction. *Medicinski Arhiv = Medical Archives = Archives De Médecine*, **2016**, 70, 449-452	1.2	4
13	2010 Update: Guidelines for the management of benign prostatic hyperplasia. *Canadian Urological Association Journal*, **2010**, 4, 310-6	1.2	78
12	PHYTOTHERAPEUTIC APPROACH TO BENIGN PROSTATIC HYPERPLASIA TREATMENT BY PUMPKIN SEED (CUCURBITA PEPO L., CUCURBITACEAE). *Acta Medica Medianae*, **2016**, 55, 76-84	0	3
11	Prostata. **2004**, 227-258		
10	Moderne terapie dell'IPB e pattern RM post-trattamento. **2010**, 187-196		
9	[CLINICOPATHOLOGICAL STUDY OF PROSTATE BIOPSY IN PATIENTS RECEIVING DUTASTERIDE FOR BENIGN PROSTATIC HYPERPLASIA]. *Japanese Journal of Urology*, **2015**, 106, 156-62		
8	Epidemiological, Clinical and Management of Benign Prostatic Hypertrophia in Urologie Department in N'Djamena, Chad. *Open Journal of Urology*, **2017**, 07, 9-15	0.2	

7	La pr□tata: generalidades y patolog□s m□ frecuentes. *Revista De La Facultad De Medicina, Universidad Nacional Autonoma De Mexico*, **2019**, 62, 41-54	0.1	0
6	Impact of Bladder Neck Stiffness on Lower Urinary Tract Symptoms in Patient With Benign Prostatic Hyperplasia. *The Korean Journal of Urological Oncology*, **2019**, 17, 143-149	0.1	
5	Failure of Urinary Drainage: Lower Tract. **2007**, 118-131		1
4	The Clinical Benefits of Dutasteride Treatment for LUTS and BPH. *Reviews in Urology*, **2004**, 6 Suppl 9, S22-30	1	9
3	Treatment of Benign Prostatic Hyperplasia by Natural Drugs. *Molecules*, **2021**, 26,	4.8	6
2	Functional Results after First- and Second-Generation Temporary Implantable Nitinol Device (TIND) for BPH: A Narrative Review of the Literature. *Current Bladder Dysfunction Reports*, 1	0.4	
1	Benign prostatic hyperplasia morphological parameters for assessing risk of acute urinary retention. *African Journal of Urology*, **2022**, 28,	1	